<DOC>
	<DOCNO>NCT01691820</DOCNO>
	<brief_summary>The purpose study estimate incidence CMV secondary infection ( re-infections/re-activations ) incidence CMV primary infection adolescent female .</brief_summary>
	<brief_title>A Study Adolescent Females Explore Cytomegalovirus Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>A female adolescent , include 10 17 year time enrolment regardless pregnancy status contraception method use use . Subjects investigator believe subject and/or subject 's parent ( ) /Legally Acceptable Representative ( ) ( LAR [ ] ) comply requirement protocol . Written inform assent and/or consent obtain subject and/or parent ( ) /LAR ( ) subject . Subject likely remain area and/or return require study Site Visits complete Sample Collection Visits . Child care . Use plan use investigational nonregistered antiviral drug vaccine study period . Known medical history recurrent clinical herpes episode require episodic chronic suppressive treatment oral parenteral antiviral treatment acyclovir , famciclovir , valacyclovir antiherpes virus antiviral year precede enrolment . Topical antiviral allow . Subjects history previous vaccination CMV . Chronic administration immunosuppressant immunemodifying drug within 6 month prior Visit 1 plan administration study . Inhaled topical steroid allow . Administration immunoglobulins and/or blood product within 3 month prior Visit 1 plan administration study . Any confirm suspected immunosuppressive immunodeficient condition include HIVinfection , base medical history physical examination ( laboratory testing require ) . Any major congenital defect , serious chronic illness organ transplantation .</criteria>
	<gender>Female</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Adolescent female</keyword>
	<keyword>Cytomegalovirus ( CMV )</keyword>
</DOC>